Other evaluated clinical characteristics, including age, sex, the history of alcohol use, site of metastasis, Child‐Pugh stage, BCLC stage, AFP concentration, macrovascular invasion, HBV infection, liver cirrhosis, and prior treatment, did not significantly influence the efficacy of PD‐1 inhibitor plus antiangiogenic agent toward HCC patients (Table 2). This evidence concerns the gene AFP and hepatocellular carcinoma.